<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01426438</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG A5293</org_study_id>
    <secondary_id>1U01AI068636</secondary_id>
    <nct_id>NCT01426438</nct_id>
  </id_info>
  <brief_title>Endothelial Function, Lipoproteins, and Inflammation With Low HDL Cholesterol in HIV: ER Niacin Versus Fenofibrate</brief_title>
  <official_title>Effect of HDL-Raising Therapies on Endothelial Function, Lipoproteins, and Inflammation in HIV-infected Subjects With Low HDL Cholesterol: A Phase II Randomized Trial of Extended Release Niacin vs. Fenofibrate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AIDS Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>AIDS Clinical Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done with people with HIV infection who have low levels of HDL-C. HDL-C
      is a type of &quot;good&quot; cholesterol. People with low HDL-C have a higher risk of heart disease
      and may have problems with how their blood vessels relax. The endothelium is the inner lining
      of all blood vessels, such as arteries and veins. When the endothelium is not working
      properly, the blood vessels have trouble expanding properly, which contributes to the
      development of heart and blood vessel disease.

      The main purpose of this study is to see if taking either extended-release niacin or
      fenofibrate for 24 weeks will help blood vessels work better by improving endothelial
      function and increasing HDL-C. Niacin and fenofibrate are medications that raise HDL-C. This
      study will also help determine how safe extended-release niacin and fenofibrate are.

      The analysis is an as-treated analysis of participants who completed study treatment and had
      a week 24 BART scan. Safety analyses include all participants
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute Change in Relative FMD (%)</measure>
    <time_frame>0 and 24 weeks</time_frame>
    <description>The absolute change in maximum relative flow mediated dilation (FMD) (%) of the brachial artery from baseline to week 24.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Cholesterol</measure>
    <time_frame>0 and 24 weeks</time_frame>
    <description>Absolute change in total cholesterol from week 0 to week 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Triglycerides</measure>
    <time_frame>0 and 24 weeks</time_frame>
    <description>Change in Triglycerides (mg/dL) from week 0 to week 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Men: Change in HDL Cholesterol</measure>
    <time_frame>0 and 24 weeks</time_frame>
    <description>Among men, change in HDL Cholesterol (mg/dL) from week 0 to week 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Women: Change in HDL Cholesterol</measure>
    <time_frame>0 and 24 weeks</time_frame>
    <description>Among women, change in HDL cholesterol (mg/dL) from week 0 to week 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HDL Particles</measure>
    <time_frame>0 and 24 weeks</time_frame>
    <description>Change in total HDL particles from week 0 to week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Non-HDL Cholesterol</measure>
    <time_frame>0 and 24 weeks</time_frame>
    <description>Change in non-HDL Cholesterol (mg/dL) from week 0 to week 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in LDL Cholesterol</measure>
    <time_frame>0 and 24 weeks</time_frame>
    <description>Change in LDL cholesterol (mg/dL) from week 0 to week 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Small LDL Particles</measure>
    <time_frame>0 and 24 weeks</time_frame>
    <description>Change in Small LDL particles from week 0 to week 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Large HDL Particles</measure>
    <time_frame>0 and 24 weeks</time_frame>
    <description>Change in Large HDL Particles from week 0 to week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HOMA-IR</measure>
    <time_frame>0 and 24 weeks</time_frame>
    <description>Absolute change from week 0 to week 24 in insulin resistance as estimated by HOMA-IR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in IL-6</measure>
    <time_frame>0 and 24 weeks</time_frame>
    <description>Change in IL-6 from week 0 to week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in C-reactive Protein (CRP)</measure>
    <time_frame>0 and 24 weeks</time_frame>
    <description>Change in C-reactive protein from week 0 to week 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in D-Dimer</measure>
    <time_frame>0 and 24 weeks</time_frame>
    <description>Change in D-Dimer from week 0 to week 24</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">99</enrollment>
  <condition>HIV-1 Infection</condition>
  <arm_group>
    <arm_group_label>Arm A: Extended-release niacin with aspirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Fenofibrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Niacin</intervention_name>
    <description>Extended-release niacin will be given with aspirin 325 mg by mouth in the evening and dose-escalated as follows: 500 mg once daily for 4 weeks, 1000 mg once daily for 4 weeks, then 1500 mg once daily for 16 weeks (through week 24)</description>
    <arm_group_label>Arm A: Extended-release niacin with aspirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Aspirin 325 mg will be given by mouth in the evening with extended-release niacin through week 24.</description>
    <arm_group_label>Arm A: Extended-release niacin with aspirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fenofibrate</intervention_name>
    <description>Fenofibrate will be administered as 200 mg by mouth once daily for 24 weeks.</description>
    <arm_group_label>Arm B: Fenofibrate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-1 infection

          -  Currently on continuous ART for ≥48 weeks.

          -  CD4+ cell count ≥100/mm3 obtained within 60 days prior to study entry.

          -  Most recent HIV-1 RNA below the limit of detection using an ultrasensitive licensed or
             FDA-approved assay obtained within 60 days prior to study entry.

          -  Certain laboratory values obtained within 60 days prior to study entry (as indicated
             in the protocol).

          -  HDL-C ≤ 40 mg/dL for men or ≤ 50 mg/dL for women within 60 days prior to study entry
             by any local assay.

          -  Fasting triglycerides 150-800 mg/dL within 60 days prior to study entry, (initially
             200-800 mg/dL, amended during study conduct).

          -  LDL-C &lt; 160 mg/dL within 60 days prior to study entry.

          -  For women of reproductive potential, negative serum or urine pregnancy test with a
             sensitivity of 15-25 mIU/mL within 60 days prior to entry.

          -  Female subjects of reproductive potential must agree to use a reliable method of
             contraception while receiving study drug and for 6 weeks after stopping study drug.

        Exclusion Criteria:

          -  Anticipation of changing ART.

          -  Intent to initiate or change the dose of lipid-lowering drugs or antihypertensives
             during study.

          -  Active acute infection or other serious illness requiring systemic treatment and/or
             hospitalization until subject either completes or is clinically stable on therapy in
             the opinion of the site investigator.

          -  Untreated hypogonadism

          -  History of physician-diagnosed diabetes mellitus or currently taking glucose-lowering
             medication, (amended during study conduct to allow well-controlled diabetics who are
             diet controlled or on stable antidiabetic treatment of metformin, sulfonylurea,
             meglitinides or alpha-glucosidase inhibitors).

          -  Hormonal anabolic therapies within 90 days prior to study entry.

          -  Uncontrolled hypertension within 60 days of study entry.

          -  Acute symptoms of gout within 60 days prior to study entry.

          -  Active peptic ulcer disease as defined by a health care professional. Treatment for
             gastroesophageal reflux disease (GERD) is not exclusionary.

          -  Documented untreated hypothyroidism per subject's medical records.

          -  Use of thyroid hormone supplements other than for treatment of hypothyroidism within
             30 days prior to entry.

          -  Active or symptomatic gallbladder disease within 1 year of study entry.

          -  Active cancer requiring systemic chemotherapy or radiation within 1 year of study
             entry.

          -  Lipid-lowering agents within 30 days prior to study entry.

          -  Use of fish oil with DHA/EPA &gt;1000 mg/day within 30 days prior to entry.

          -  Niacin or niacin-containing products that contain &gt;100 mg daily within 30 days prior
             to study entry.

          -  Use of vitamin E supplements greater than 200 IU/day within 30 days prior to entry.

          -  Use of vitamin C supplements greater than 250 mg/day within 30 days prior to entry.

          -  Use of systemic cancer chemotherapy, immunomodulators (e.g., growth factors, immune
             globulin, interleukins, and interferons) within 90 days prior to study entry.

          -  Any systemic glucocorticoid above replacement levels, defined as the equivalent of ≥
             7.5 mg of prednisone daily, within 60 days prior to study entry.

          -  Allergy, sensitivity, or severe intolerance to both aspirin and naproxen (Aleve,
             Naprosyn).

          -  Symptomatic pancreatitis with hospitalization.

          -  Pregnancy or currently breastfeeding.

          -  Active drug or alcohol use or dependence that, in the opinion of the site
             investigator, would interfere with adherence to study requirements.

          -  Currently taking or anticipation of starting medication during the study for hepatitis
             C including interferon and ribavirin.

          -  Documented history of macular edema.

          -  Current severe congestive heart failure (New York Heart Association [NYHA] Class III
             or IV).

          -  History of or current diagnosis of coronary artery disease, angina pectoris,
             myocardial infarction, previous coronary artery intervention (stenting, angioplasty),
             peripheral arterial disease (claudication, peripheral arterial angioplasty, or
             peripheral arterial bypass procedure), cerebrovascular disease (stroke or transient
             ischemic attack with documented carotid or aortic atherosclerosis), or abdominal
             aortic aneurysm.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael P Dube, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James H Stein, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Wisconsin School of Medicine and Public Health (Northwestern University CRS)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alabama Therapeutics CRS (5801)</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Southern California (1201)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033-1079</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA CARE Center CRS (601)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harbor-UCLA Med. Ctr. CRS (603)</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital CRS (6101)</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University CRS (2701)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Jersey Medical School-Adult Clinical Research Ctr. CRS (31477)</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NY Univ. HIV/AIDS CRS (401)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unc Aids Crs (3201)</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Univ. Med. Ctr. Adult CRS (1601)</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moses H. Cone Memorial Hospital CRS (3203)</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Cincinnati CRS (2401)</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case CRS (2501)</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington AIDS CRS (1401)</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>International Conference on Harmonisation. E2A: Clinical Safety Data Management : Definitions and Standards for Expedited Reporting. Website: http://www.ich.org/products/guidelines/efficacy/efficacy-single/article/clinical-safety-data-management-definitions-and-standards-for-expedited-reporting.html. Accessed May 24, 2011.</citation>
  </reference>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2011</study_first_submitted>
  <study_first_submitted_qc>August 30, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2011</study_first_posted>
  <results_first_submitted>October 15, 2014</results_first_submitted>
  <results_first_submitted_qc>October 15, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 21, 2014</results_first_posted>
  <last_update_submitted>January 4, 2016</last_update_submitted>
  <last_update_submitted_qc>January 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Fenofibrate</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A5293 opened to accrual under protocol version 1.0 on November 8, 2011. The first participant was enrolled on January 10, 2012. Accrual to the study closed on April 24, 2013, with a total of 99 participants enrolled from 11 sites within the US.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm A: Extended-release Niacin With Aspirin</title>
          <description>Niacin: Extended-release niacin given with aspirin 325 mg by mouth in the evening and dose-escalated as follows: 500 mg once daily for 4 weeks, 1000 mg once daily for 4 weeks, then 1500 mg once daily for 16 weeks (through week 24)
Aspirin: Aspirin 325 mg given by mouth in the evening with extended-release niacin through week 24.</description>
        </group>
        <group group_id="P2">
          <title>Arm B: Fenofibrate</title>
          <description>Fenofibrate: Fenofibrate administered as 200 mg by mouth once daily for 24 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Off study Treatment</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Poor scan quality</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missed Scan</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm A: Extended-release Niacin With Aspirin</title>
          <description>Niacin: Extended-release niacin given with aspirin 325 mg by mouth in the evening and dose-escalated as follows: 500 mg once daily for 4 weeks, 1000 mg once daily for 4 weeks, then 1500 mg once daily for 16 weeks (through week 24)
Aspirin: Aspirin 325 mg given by mouth in the evening with extended-release niacin through week 24.</description>
        </group>
        <group group_id="B2">
          <title>Arm B: Fenofibrate</title>
          <description>Fenofibrate: Fenofibrate administered as 200 mg by mouth once daily for 24 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
            <count group_id="B2" value="39"/>
            <count group_id="B3" value="74"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46" lower_limit="37" upper_limit="50"/>
                    <measurement group_id="B2" value="45" lower_limit="38" upper_limit="51"/>
                    <measurement group_id="B3" value="45" lower_limit="38" upper_limit="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White, non-Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black, non-Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic, regardless of race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian, Alaskan Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Current Smoker</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>10 year Coronary Heart Disease (CHD) risk</title>
          <units>10yr Framingham CHD risk (%)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3" lower_limit="1" upper_limit="6"/>
                    <measurement group_id="B2" value="3" lower_limit="1" upper_limit="10"/>
                    <measurement group_id="B3" value="3" lower_limit="1" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Relative FMD</title>
          <units>%</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.38" lower_limit="2.88" upper_limit="6.76"/>
                    <measurement group_id="B2" value="3.93" lower_limit="2.61" upper_limit="8.05"/>
                    <measurement group_id="B3" value="4.21" lower_limit="2.76" upper_limit="6.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Cholesterol</title>
          <description>Niacin + Aspirin N=34; Fenofibrate N=39.</description>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="185" lower_limit="171" upper_limit="212"/>
                    <measurement group_id="B2" value="184" lower_limit="159" upper_limit="211"/>
                    <measurement group_id="B3" value="184" lower_limit="165" upper_limit="211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Triglycerides</title>
          <description>Niacin + Aspirin N=34; Fenofibrate N=39.</description>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="254" lower_limit="198" upper_limit="360"/>
                    <measurement group_id="B2" value="206" lower_limit="171" upper_limit="293"/>
                    <measurement group_id="B3" value="232" lower_limit="176" upper_limit="308"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>High Density Lipoprotein (HDL)-Cholesterol</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Very low HDL-C (&lt; 30 mg/dL (Men)/&lt; 40 mg/dL (W))</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low HDL-C (30-40 mg/dL (Men)/40-50 mg/dL (Women))</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Men: HDL Cholesterol</title>
          <description>Since the eligibility requirements for HDL cholesterol differed for men and women, HDL cholesterol is reported separately for men and women.
Niacin + Aspirin N=27; Fenofibrate N=30.</description>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32" lower_limit="30" upper_limit="35"/>
                    <measurement group_id="B2" value="36" lower_limit="29" upper_limit="39"/>
                    <measurement group_id="B3" value="33" lower_limit="30" upper_limit="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Women: HDL Cholesterol</title>
          <description>Since the eligibility requirements for HDL cholesterol differed for men and women, HDL cholesterol is reported separately for men and women.
Niacin + Aspirin N=7; Fenofibrate N=9.</description>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37" lower_limit="36" upper_limit="49"/>
                    <measurement group_id="B2" value="38" lower_limit="35" upper_limit="42"/>
                    <measurement group_id="B3" value="38" lower_limit="36" upper_limit="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HDL Particles</title>
          <units>nmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.8" lower_limit="28.4" upper_limit="35.4"/>
                    <measurement group_id="B2" value="30.2" lower_limit="26.7" upper_limit="33.2"/>
                    <measurement group_id="B3" value="31.3" lower_limit="27.2" upper_limit="34.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Non-HDL Cholesterol</title>
          <description>Niacin + Aspirin N=34; Fenofibrate N=39.</description>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="150" lower_limit="135" upper_limit="169"/>
                    <measurement group_id="B2" value="153" lower_limit="123" upper_limit="175"/>
                    <measurement group_id="B3" value="150" lower_limit="128" upper_limit="169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Low Density Lipoprotein (LDL) Cholesterol</title>
          <description>Niacin + Aspirin N=29; Fenofibrate N=36.</description>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="103" lower_limit="88" upper_limit="117"/>
                    <measurement group_id="B2" value="101" lower_limit="84" upper_limit="120"/>
                    <measurement group_id="B3" value="103" lower_limit="86" upper_limit="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Small LDL Particles</title>
          <units>nmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1018" lower_limit="803" upper_limit="1133"/>
                    <measurement group_id="B2" value="1052" lower_limit="823" upper_limit="1222"/>
                    <measurement group_id="B3" value="1022" lower_limit="816" upper_limit="1161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Large HDL Particles</title>
          <units>nmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.1" lower_limit="1.4" upper_limit="3.2"/>
                    <measurement group_id="B2" value="2.6" lower_limit="1.5" upper_limit="3.7"/>
                    <measurement group_id="B3" value="2.5" lower_limit="1.5" upper_limit="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HOMA-IR (Homeostatic model assessment - Insulin Resistance)</title>
          <description>Niacin + Aspirin N=34; Fenofibrate N=39.</description>
          <units>HOMA IR Score</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.5" lower_limit="1.9" upper_limit="4.5"/>
                    <measurement group_id="B2" value="3.2" lower_limit="2.6" upper_limit="5.3"/>
                    <measurement group_id="B3" value="3.1" lower_limit="2.1" upper_limit="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Interleukin(IL)-6</title>
          <description>Niacin + Aspirin N=34; Fenofibrate N=35.</description>
          <units>pg/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.1" lower_limit="0.8" upper_limit="2.2"/>
                    <measurement group_id="B2" value="1.5" lower_limit="0.8" upper_limit="2.2"/>
                    <measurement group_id="B3" value="1.3" lower_limit="0.8" upper_limit="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>C-reactive protein</title>
          <units>ug/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.9" lower_limit="1.0" upper_limit="5.4"/>
                    <measurement group_id="B2" value="1.5" lower_limit="0.7" upper_limit="3.9"/>
                    <measurement group_id="B3" value="1.7" lower_limit="0.8" upper_limit="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>D-Dimer</title>
          <units>ug/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.30" lower_limit="0.22" upper_limit="0.37"/>
                    <measurement group_id="B2" value="0.25" lower_limit="0.19" upper_limit="0.46"/>
                    <measurement group_id="B3" value="0.29" lower_limit="0.19" upper_limit="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Absolute Change in Relative FMD (%)</title>
        <description>The absolute change in maximum relative flow mediated dilation (FMD) (%) of the brachial artery from baseline to week 24.</description>
        <time_frame>0 and 24 weeks</time_frame>
        <population>This is an as-treated analysis limited to 74 participants who had 24 weeks of follow up and a useable week 24 scan.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: Extended-release Niacin With Aspirin</title>
            <description>Niacin: Extended-release niacin given with aspirin 325 mg by mouth in the evening and dose-escalated as follows: 500 mg once daily for 4 weeks, 1000 mg once daily for 4 weeks, then 1500 mg once daily for 16 weeks (through week 24)
Aspirin: Aspirin 325 mg given by mouth in the evening with extended-release niacin through week 24.</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Fenofibrate</title>
            <description>Fenofibrate: Fenofibrate administered as 200 mg by mouth once daily for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in Relative FMD (%)</title>
          <description>The absolute change in maximum relative flow mediated dilation (FMD) (%) of the brachial artery from baseline to week 24.</description>
          <population>This is an as-treated analysis limited to 74 participants who had 24 weeks of follow up and a useable week 24 scan.</population>
          <units>% FMD</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.60" lower_limit="-1.58" upper_limit="2.28"/>
                    <measurement group_id="O2" value="0.50" lower_limit="-0.97" upper_limit="2.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.28</p_value>
            <method>Sign test</method>
            <method_desc>Stratified exact Wilcoxon signed rank test. Stratified by screening HDL-C level and statin use within 90 days prior to study entry.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.19</p_value>
            <method>Sign test</method>
            <method_desc>Stratified exact Wilcoxon signed rank test. Stratified by screening HDL-C level and statin use within 90 days prior to study entry.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Cholesterol</title>
        <description>Absolute change in total cholesterol from week 0 to week 24.</description>
        <time_frame>0 and 24 weeks</time_frame>
        <population>This is an as-treated analysis limited to 74 participants who had 24 weeks of follow up and a useable week 24 scan and had lipid panels at weeks 0 and 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: Extended-release Niacin With Aspirin</title>
            <description>Niacin: Extended-release niacin given with aspirin 325 mg by mouth in the evening and dose-escalated as follows: 500 mg once daily for 4 weeks, 1000 mg once daily for 4 weeks, then 1500 mg once daily for 16 weeks (through week 24)
Aspirin: Aspirin 325 mg given by mouth in the evening with extended-release niacin through week 24.</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Fenofibrate</title>
            <description>Fenofibrate: Fenofibrate administered as 200 mg by mouth once daily for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cholesterol</title>
          <description>Absolute change in total cholesterol from week 0 to week 24.</description>
          <population>This is an as-treated analysis limited to 74 participants who had 24 weeks of follow up and a useable week 24 scan and had lipid panels at weeks 0 and 24.</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9" lower_limit="-26" upper_limit="3"/>
                    <measurement group_id="O2" value="-2" lower_limit="-28" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Triglycerides</title>
        <description>Change in Triglycerides (mg/dL) from week 0 to week 24.</description>
        <time_frame>0 and 24 weeks</time_frame>
        <population>This is an as-treated analysis limited to 74 participants who had 24 weeks of follow up and a useable week 24 scan.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: Extended-release Niacin With Aspirin</title>
            <description>Niacin: Extended-release niacin given with aspirin 325 mg by mouth in the evening and dose-escalated as follows: 500 mg once daily for 4 weeks, 1000 mg once daily for 4 weeks, then 1500 mg once daily for 16 weeks (through week 24)
Aspirin: Aspirin 325 mg given by mouth in the evening with extended-release niacin through week 24.</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Fenofibrate</title>
            <description>Fenofibrate: Fenofibrate administered as 200 mg by mouth once daily for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Triglycerides</title>
          <description>Change in Triglycerides (mg/dL) from week 0 to week 24.</description>
          <population>This is an as-treated analysis limited to 74 participants who had 24 weeks of follow up and a useable week 24 scan.</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-65" lower_limit="-163" upper_limit="8"/>
                    <measurement group_id="O2" value="-54" lower_limit="-113" upper_limit="-10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Men: Change in HDL Cholesterol</title>
        <description>Among men, change in HDL Cholesterol (mg/dL) from week 0 to week 24.</description>
        <time_frame>0 and 24 weeks</time_frame>
        <population>Men in the as-treated analysis population, limited to 74 participants who had 24 weeks of follow up and a useable week 24 scan.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: Extended-release Niacin With Aspirin</title>
            <description>Niacin: Extended-release niacin given with aspirin 325 mg by mouth in the evening and dose-escalated as follows: 500 mg once daily for 4 weeks, 1000 mg once daily for 4 weeks, then 1500 mg once daily for 16 weeks (through week 24)
Aspirin: Aspirin 325 mg given by mouth in the evening with extended-release niacin through week 24.</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Fenofibrate</title>
            <description>Fenofibrate: Fenofibrate administered as 200 mg by mouth once daily for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Men: Change in HDL Cholesterol</title>
          <description>Among men, change in HDL Cholesterol (mg/dL) from week 0 to week 24.</description>
          <population>Men in the as-treated analysis population, limited to 74 participants who had 24 weeks of follow up and a useable week 24 scan.</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="0" upper_limit="9"/>
                    <measurement group_id="O2" value="6.5" lower_limit="0" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Women: Change in HDL Cholesterol</title>
        <description>Among women, change in HDL cholesterol (mg/dL) from week 0 to week 24.</description>
        <time_frame>0 and 24 weeks</time_frame>
        <population>Women in the as-treated analysis population, limited to 74 participants who had 24 weeks of follow up and a useable week 24 scan.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: Extended-release Niacin With Aspirin</title>
            <description>Niacin: Extended-release niacin given with aspirin 325 mg by mouth in the evening and dose-escalated as follows: 500 mg once daily for 4 weeks, 1000 mg once daily for 4 weeks, then 1500 mg once daily for 16 weeks (through week 24)
Aspirin: Aspirin 325 mg given by mouth in the evening with extended-release niacin through week 24.</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Fenofibrate</title>
            <description>Fenofibrate: Fenofibrate administered as 200 mg by mouth once daily for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Women: Change in HDL Cholesterol</title>
          <description>Among women, change in HDL cholesterol (mg/dL) from week 0 to week 24.</description>
          <population>Women in the as-treated analysis population, limited to 74 participants who had 24 weeks of follow up and a useable week 24 scan.</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="-1" upper_limit="22"/>
                    <measurement group_id="O2" value="8" lower_limit="5" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in HDL Particles</title>
        <description>Change in total HDL particles from week 0 to week 24</description>
        <time_frame>0 and 24 weeks</time_frame>
        <population>This is an as-treated analysis limited to 74 participants who had 24 weeks of follow up and a useable week 24 scan.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: Extended-release Niacin With Aspirin</title>
            <description>Niacin: Extended-release niacin given with aspirin 325 mg by mouth in the evening and dose-escalated as follows: 500 mg once daily for 4 weeks, 1000 mg once daily for 4 weeks, then 1500 mg once daily for 16 weeks (through week 24)
Aspirin: Aspirin 325 mg given by mouth in the evening with extended-release niacin through week 24.</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Fenofibrate</title>
            <description>Fenofibrate: Fenofibrate administered as 200 mg by mouth once daily for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HDL Particles</title>
          <description>Change in total HDL particles from week 0 to week 24</description>
          <population>This is an as-treated analysis limited to 74 participants who had 24 weeks of follow up and a useable week 24 scan.</population>
          <units>nmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" lower_limit="-4.3" upper_limit="2.1"/>
                    <measurement group_id="O2" value="4.3" lower_limit="1.8" upper_limit="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Non-HDL Cholesterol</title>
        <description>Change in non-HDL Cholesterol (mg/dL) from week 0 to week 24.</description>
        <time_frame>0 and 24 weeks</time_frame>
        <population>This is an as-treated analysis limited to 74 participants who had 24 weeks of follow up and a useable week 24 scan.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: Extended-release Niacin With Aspirin</title>
            <description>Niacin: Extended-release niacin given with aspirin 325 mg by mouth in the evening and dose-escalated as follows: 500 mg once daily for 4 weeks, 1000 mg once daily for 4 weeks, then 1500 mg once daily for 16 weeks (through week 24)
Aspirin: Aspirin 325 mg given by mouth in the evening with extended-release niacin through week 24.</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Fenofibrate</title>
            <description>Fenofibrate: Fenofibrate administered as 200 mg by mouth once daily for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Non-HDL Cholesterol</title>
          <description>Change in non-HDL Cholesterol (mg/dL) from week 0 to week 24.</description>
          <population>This is an as-treated analysis limited to 74 participants who had 24 weeks of follow up and a useable week 24 scan.</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17" lower_limit="-29" upper_limit="4"/>
                    <measurement group_id="O2" value="-4" lower_limit="-28" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in LDL Cholesterol</title>
        <description>Change in LDL cholesterol (mg/dL) from week 0 to week 24.</description>
        <time_frame>0 and 24 weeks</time_frame>
        <population>This is an as-treated analysis limited to 74 participants who had 24 weeks of follow up and a useable week 24 scan.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: Extended-release Niacin With Aspirin</title>
            <description>Niacin: Extended-release niacin given with aspirin 325 mg by mouth in the evening and dose-escalated as follows: 500 mg once daily for 4 weeks, 1000 mg once daily for 4 weeks, then 1500 mg once daily for 16 weeks (through week 24)
Aspirin: Aspirin 325 mg given by mouth in the evening with extended-release niacin through week 24.</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Fenofibrate</title>
            <description>Fenofibrate: Fenofibrate administered as 200 mg by mouth once daily for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in LDL Cholesterol</title>
          <description>Change in LDL cholesterol (mg/dL) from week 0 to week 24.</description>
          <population>This is an as-treated analysis limited to 74 participants who had 24 weeks of follow up and a useable week 24 scan.</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" lower_limit="-14" upper_limit="12"/>
                    <measurement group_id="O2" value="7" lower_limit="-13" upper_limit="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Small LDL Particles</title>
        <description>Change in Small LDL particles from week 0 to week 24.</description>
        <time_frame>0 and 24 weeks</time_frame>
        <population>This is an as-treated analysis limited to 74 participants who had 24 weeks of follow up and a useable week 24 scan.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: Extended-release Niacin With Aspirin</title>
            <description>Niacin: Extended-release niacin given with aspirin 325 mg by mouth in the evening and dose-escalated as follows: 500 mg once daily for 4 weeks, 1000 mg once daily for 4 weeks, then 1500 mg once daily for 16 weeks (through week 24)
Aspirin: Aspirin 325 mg given by mouth in the evening with extended-release niacin through week 24.</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Fenofibrate</title>
            <description>Fenofibrate: Fenofibrate administered as 200 mg by mouth once daily for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Small LDL Particles</title>
          <description>Change in Small LDL particles from week 0 to week 24.</description>
          <population>This is an as-treated analysis limited to 74 participants who had 24 weeks of follow up and a useable week 24 scan.</population>
          <units>nmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-176" lower_limit="-410" upper_limit="-19"/>
                    <measurement group_id="O2" value="-119" lower_limit="-320" upper_limit="-17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Large HDL Particles</title>
        <description>Change in Large HDL Particles from week 0 to week 24</description>
        <time_frame>0 and 24 weeks</time_frame>
        <population>This is an as-treated analysis limited to 74 participants who had 24 weeks of follow up and a useable week 24 scan.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: Extended-release Niacin With Aspirin</title>
            <description>Niacin: Extended-release niacin given with aspirin 325 mg by mouth in the evening and dose-escalated as follows: 500 mg once daily for 4 weeks, 1000 mg once daily for 4 weeks, then 1500 mg once daily for 16 weeks (through week 24)
Aspirin: Aspirin 325 mg given by mouth in the evening with extended-release niacin through week 24.</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Fenofibrate</title>
            <description>Fenofibrate: Fenofibrate administered as 200 mg by mouth once daily for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Large HDL Particles</title>
          <description>Change in Large HDL Particles from week 0 to week 24</description>
          <population>This is an as-treated analysis limited to 74 participants who had 24 weeks of follow up and a useable week 24 scan.</population>
          <units>nmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" lower_limit="0.1" upper_limit="3.3"/>
                    <measurement group_id="O2" value="-0.3" lower_limit="-0.9" upper_limit="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in HOMA-IR</title>
        <description>Absolute change from week 0 to week 24 in insulin resistance as estimated by HOMA-IR</description>
        <time_frame>0 and 24 weeks</time_frame>
        <population>This is an as-treated analysis limited to 74 participants who had 24 weeks of follow up and a useable week 24 scan.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: Extended-release Niacin With Aspirin</title>
            <description>Niacin: Extended-release niacin given with aspirin 325 mg by mouth in the evening and dose-escalated as follows: 500 mg once daily for 4 weeks, 1000 mg once daily for 4 weeks, then 1500 mg once daily for 16 weeks (through week 24)
Aspirin: Aspirin 325 mg given by mouth in the evening with extended-release niacin through week 24.</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Fenofibrate</title>
            <description>Fenofibrate: Fenofibrate administered as 200 mg by mouth once daily for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HOMA-IR</title>
          <description>Absolute change from week 0 to week 24 in insulin resistance as estimated by HOMA-IR</description>
          <population>This is an as-treated analysis limited to 74 participants who had 24 weeks of follow up and a useable week 24 scan.</population>
          <units>HOMA IR Score</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" lower_limit="0.0" upper_limit="3.0"/>
                    <measurement group_id="O2" value="0.3" lower_limit="-1.2" upper_limit="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in IL-6</title>
        <description>Change in IL-6 from week 0 to week 24</description>
        <time_frame>0 and 24 weeks</time_frame>
        <population>This is an as-treated analysis limited to 74 participants who had 24 weeks of follow up and a useable week 24 scan.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: Extended-release Niacin With Aspirin</title>
            <description>Niacin: Extended-release niacin given with aspirin 325 mg by mouth in the evening and dose-escalated as follows: 500 mg once daily for 4 weeks, 1000 mg once daily for 4 weeks, then 1500 mg once daily for 16 weeks (through week 24)
Aspirin: Aspirin 325 mg given by mouth in the evening with extended-release niacin through week 24.</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Fenofibrate</title>
            <description>Fenofibrate: Fenofibrate administered as 200 mg by mouth once daily for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in IL-6</title>
          <description>Change in IL-6 from week 0 to week 24</description>
          <population>This is an as-treated analysis limited to 74 participants who had 24 weeks of follow up and a useable week 24 scan.</population>
          <units>pg/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="-1.1" upper_limit="0.8"/>
                    <measurement group_id="O2" value="0.2" lower_limit="-0.7" upper_limit="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in C-reactive Protein (CRP)</title>
        <description>Change in C-reactive protein from week 0 to week 24.</description>
        <time_frame>0 and 24 weeks</time_frame>
        <population>This is an as-treated analysis limited to 74 participants who had 24 weeks of follow up and a useable week 24 scan.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: Extended-release Niacin With Aspirin</title>
            <description>Niacin: Extended-release niacin given with aspirin 325 mg by mouth in the evening and dose-escalated as follows: 500 mg once daily for 4 weeks, 1000 mg once daily for 4 weeks, then 1500 mg once daily for 16 weeks (through week 24)
Aspirin: Aspirin 325 mg given by mouth in the evening with extended-release niacin through week 24.</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Fenofibrate</title>
            <description>Fenofibrate: Fenofibrate administered as 200 mg by mouth once daily for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in C-reactive Protein (CRP)</title>
          <description>Change in C-reactive protein from week 0 to week 24.</description>
          <population>This is an as-treated analysis limited to 74 participants who had 24 weeks of follow up and a useable week 24 scan.</population>
          <units>ug/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" lower_limit="-3.0" upper_limit="2.6"/>
                    <measurement group_id="O2" value="0.7" lower_limit="-2.1" upper_limit="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in D-Dimer</title>
        <description>Change in D-Dimer from week 0 to week 24</description>
        <time_frame>0 and 24 weeks</time_frame>
        <population>This is an as-treated analysis limited to 74 participants who had 24 weeks of follow up and a useable week 24 scan.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: Extended-release Niacin With Aspirin</title>
            <description>Niacin: Extended-release niacin given with aspirin 325 mg by mouth in the evening and dose-escalated as follows: 500 mg once daily for 4 weeks, 1000 mg once daily for 4 weeks, then 1500 mg once daily for 16 weeks (through week 24)
Aspirin: Aspirin 325 mg given by mouth in the evening with extended-release niacin through week 24.</description>
          </group>
          <group group_id="O2">
            <title>Arm B: Fenofibrate</title>
            <description>Fenofibrate: Fenofibrate administered as 200 mg by mouth once daily for 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in D-Dimer</title>
          <description>Change in D-Dimer from week 0 to week 24</description>
          <population>This is an as-treated analysis limited to 74 participants who had 24 weeks of follow up and a useable week 24 scan.</population>
          <units>ug/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" lower_limit="-0.08" upper_limit="0.20"/>
                    <measurement group_id="O2" value="0.06" lower_limit="-0.19" upper_limit="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected from randomization to the date the participant went off study.</time_frame>
      <desc>Grade≥2 nausea, vomiting diarrhea, ulcers, abnormal bleeding/bruising, and lab values. Other Grade≥3 signs/symptoms and all s/sx or labs that lead to a change in study treatment regardless of grade. Diagnoses per ACTG criteria for clinical events &amp; diseases. See DAIDS Table for Grading the Severity of Adult and pediatric AEs, V1.0.</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm A: Extended-release Niacin With Aspirin</title>
          <description>Niacin: Extended-release niacin given with aspirin 325 mg by mouth in the evening and dose-escalated as follows: 500 mg once daily for 4 weeks, 1000 mg once daily for 4 weeks, then 1500 mg once daily for 16 weeks (through week 24) Aspirin: Aspirin 325 mg given by mouth in the evening with extended-release niacin through week 24.</description>
        </group>
        <group group_id="E2">
          <title>Arm B: Fenofibrate</title>
          <description>Fenofibrate: Fenofibrate administered as 200 mg by mouth once daily for 24 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Blood glucose decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Blood phosphorus decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Blood uric acid increased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Low density lipoprotein increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>ACTG Clinicaltrials.gov Coordinator</name_or_title>
      <organization>ACTG Network Coordinating Center, Social and Scientific Systems, Inc.</organization>
      <phone>(301) 628-3313</phone>
      <email>ACTGCT.Gov@s-3.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

